Combined intravitreal Bevacizumab andPropranolol versus intravitreal Bevacizumab alone for neovascular age-related macular degeneration

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240415061498N1

Enrollment

Registered

2025-05-03

Start date

2024-12-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration. Exudative age-related macular degeneration

Interventions

Intervention 1: Intervention group: For one group, three monthly injections of propranolol and bevacizumab are performed simultaneously along with anterior chamber paracentesis. Intervention 2: Contro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Age-related Macular Degeneration Patients with vision less than 5 out of 10 Patients without a history of macular edema

Exclusion criteria

Exclusion criteria: Choroidal neovascularization History of retinal laser History of intraocular surgery in the past six months. History of glaucoma History of vitrectomy Intraocular inflammation Uncontrolled high blood pressure Kidney disease Monocular patients Pregnancy Age-related macular degeneration of the type Neovascular

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: The response rate to the Snellen chart at a distance of six meters.;The thickness of the macular area. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Retinal thickness in central 5mm based on OCT.;???? ???? ???. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Intraocular inflammation. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Neovascularization. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Optical Coherence Tomography Angiography. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through examination and registration in the checklist.	—

Measure

Time frame

Visual acuity. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: The response rate to the Snellen chart at a distance of six meters.;The thickness of the macular area. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Retinal thickness in central 5mm based on OCT.;???? ???? ???. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Intraocular inflammation. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Neovascularization. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through slit lamp examination.;Optical Coherence Tomography Angiography. Timepoint: Measurement at the beginning of the study, one week later, one month, two months and three months later. Method of measurement: Through examination and registration in the checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Shamsizade

Yazd University of Medical Sciences

M.shamsizade@gmail.com+98 35 3822 3888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026